Victoza Clinical Trials

Browse 26 Victoza Medical Studies Across 31 Cities

4 Phase 3 Trial · 38 Victoza Clinics

Clinical TrialsVictoza Clinical Trials
Reviewed by Michael Gill, B. Sc.
10 Victoza Clinical Trials Near Me
Top Cities for Victoza Clinical Trials
Image of Minneapolis in Minnesota.
Minneapolis
2Active Trials
Novo Nordisk Investigational SiteTop Active Site
Image of Buffalo in New York.
Buffalo
2Active Trials
Novo Nordisk Investigational SiteTop Active Site
Victoza Clinical Trials by Phase of Trial
N/A Victoza Clinical Trials
1Active Victoza Clinical Trials
1Number of Unique Treatments
2Number of Active Locations
Saxenda®
Most Recent Victoza Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
Receive treatment for Childhood Obesity
7/17/2023
Phase 2
Growth hormone for Healthy Subjects
5/1/2023
Phase 4
CT-868 for Type 1 Diabetes
3/21/2023
Phase 1
Semaglutide for Obesity
1/19/2023
Phase 4
Liraglutide Pen Injector for Irritable Bowel Syndrome
3/22/2022
Phase 2

What Are Victoza Clinical Trials?

Victoza is an injectable, prescription medication used to treat type 2 diabetes in adults, and children over the age of 10. It is also used to reduce the risk of heart attack, stroke, and related deaths in adults with type 2 diabetes and known heart conditions.

Victoza clinical trials are important for several reasons. First, they help to ensure that the medication is safe for use in humans. Second, they help to determine whether the medication is effective in treating diabetes. Finally, the clinical trials help to identify any side effects that may occur with the use of Victoza.

Why Is Victoza Being Studied in Clinical Trials?

Victoza is a glucagon-like peptide-1 (GLP-1) receptor agonist, meaning it mimics some of the behavior of the GLP-1 hormone. This is a hormone that is released after eating and helps to regulate blood sugar levels.

Victoza might be more effective than other diabetes medications because it acts on two pathways involved in regulating blood sugar levels. First, it increases insulin release from the pancreas. Second, it slows gastric emptying.

How Does Victoza Work?

GLP-1 is a naturally occurring hormone that is released when a person eats. GLP-1 slows the release of food from your stomach, thereby controlling blood sugar levels. If food leaves your stomach too quickly, your blood sugar levels can spike. When this happens, your pancreas needs to make extra insulin to regulate blood sugar levels. Victoza works by slowing gastric emptying and increasing insulin levels produced by the pancreas.

What Are Some of The Breakthrough Clinical Trials Involving Victoza?

Some of the recent clinical trials involving Victoza are the following:

2019: A phase 3 clinical trial testing the safety and effectiveness of Victoza as a treatment for type 2 diabetes in children and adolescents. The trial is ongoing and is expected to be completed in 2020.

2012: This clinical trial tested the safety and effectiveness of Victoza as an adjunct to insulin therapy in adults with type 1 diabetes. The study found that Victoza was safe and effective in improving blood sugar control in adults with type 1 diabetes.

Who Are The Key Opinion Leaders On Victoza Clinical Trial Research?

Dr. Satish Garg, MD is a key opinion leader on Victoza clinical trial research. Dr. Garg is a Professor of Medicine at the University of Colorado and the Director of the Diabetes Clinical Research Program at the Barbara Davis Center for Diabetes. Dr. Garg has been involved in Victoza clinical trial research since the medication was first developed. He has conducted several clinical trials testing the safety and effectiveness of Victoza in treating type 2 diabetes.

Dr. Osama Hamdy, MD, PhD, FACE is another key opinion leader on Victoza clinical trial research. Dr. Hamdy is the Medical Director of the Obesity Clinical Program at Brigham and Women’s Hospital and an Associate Professor of Medicine at Harvard Medical School. Dr. Hamdy has conducted several clinical trials testing the safety and effectiveness of Victoza in treating type 2 diabetes.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 12th, 2021

Last Reviewed: September 3rd, 2023

References1 Clerk LH, Vincent MA, Jahn LA, Liu Z, Lindner JR, Barrett EJ. Obesity blunts insulin-mediated microvascular recruitment in human forearm muscle. Diabetes. 2006 May;55(5):1436-42. doi: 10.2337/db05-1373. https://pubmed.ncbi.nlm.nih.gov/166447022 Clerk LH, Vincent MA, Jahn LA, Liu Z, Lindner JR, Barrett EJ. Obesity blunts insulin-mediated microvascular recruitment in human forearm muscle. Diabetes. 2006 May;55(5):1436-42. https://pubmed.ncbi.nlm.nih.gov/166447023 Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13. https://pubmed.ncbi.nlm.nih.gov/272954274 Liu J, Jahn LA, Fowler DE, Barrett EJ, Cao W, Liu Z. Free fatty acids induce insulin resistance in both cardiac and skeletal muscle microvasculature in humans. J Clin Endocrinol Metab. 2011 Feb;96(2):438-46. doi: 10.1210/jc.2010-1174. Epub 2010 Nov 3. https://pubmed.ncbi.nlm.nih.gov/210479225 Chai W, Liu J, Jahn LA, Fowler DE, Barrett EJ, Liu Z. Salsalate attenuates free fatty acid-induced microvascular and metabolic insulin resistance in humans. Diabetes Care. 2011 Jul;34(7):1634-8. doi: 10.2337/dc10-2345. Epub 2011 May 26. https://pubmed.ncbi.nlm.nih.gov/216170986 Barrett EJ, Wang H, Upchurch CT, Liu Z. Insulin regulates its own delivery to skeletal muscle by feed-forward actions on the vasculature. Am J Physiol Endocrinol Metab. 2011 Aug;301(2):E252-63. doi: 10.1152/ajpendo.00186.2011. Epub 2011 May 24. https://pubmed.ncbi.nlm.nih.gov/216102267 Vincent MA, Clerk LH, Lindner JR, Price WJ, Jahn LA, Leong-Poi H, Barrett EJ. Mixed meal and light exercise each recruit muscle capillaries in healthy humans. Am J Physiol Endocrinol Metab. 2006 Jun;290(6):E1191-7. doi: 10.1152/ajpendo.00497.2005. https://pubmed.ncbi.nlm.nih.gov/166824888 Barrett EJ, Wang H, Upchurch CT, Liu Z. Insulin regulates its own delivery to skeletal muscle by feed-forward actions on the vasculature. Am J Physiol Endocrinol Metab. 2011 Aug;301(2):E252-63. doi: 10.1152/ajpendo.00186.2011. Epub 2011 May 24. Review. https://pubmed.ncbi.nlm.nih.gov/216102269 Vincent MA, Clerk LH, Lindner JR, Price WJ, Jahn LA, Leong-Poi H, Barrett EJ. Mixed meal and light exercise each recruit muscle capillaries in healthy humans. Am J Physiol Endocrinol Metab. 2006 Jun;290(6):E1191-7. https://pubmed.ncbi.nlm.nih.gov/1668248810 Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004 Mar 2;109(8):962-5. Epub 2004 Feb 23. https://pubmed.ncbi.nlm.nih.gov/14981009
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top